

Assoc. Prof. Aslı ÇİFCİBAŞI ÖRMECİ

Personal Information

Office Phone: +90 414 200 0 Extension: 31140

Email: asli.cifcibasiormec@istanbul.edu.tr

Web: <http://aves.istanbul.edu.tr/3730/>

International Researcher IDs

ORCID: 0000-0001-6297-8045

Publons / Web Of Science ResearcherID: O-3507-2018

Yoksis Researcher ID: 167591

Education Information

Post Doctorate of Medicine, Istanbul University, Istanbul Medical Faculty, Division Of Medical Sciences , Turkey 2009 - 2013

Expertise In Medicine, Diğer (Kurumlar,hastaneler Vb.), Şişli Etfal Eğitim ve Araştırma Hastanesi, Şişli Etfal Eğitim ve Araştırma Hastanesi, Turkey 2003 - 2008

Undergraduate, İstanbul University-Cerrahpaşa, Cerrahpasa Faculty Of Medicine, Turkey 1996 - 2002

Research Areas

Health Sciences

Published journal articles indexed by SCI, SSCI, and AHCI

- I. **What is the effect of subepithelial lesions of the esophagus on esophageal motility?**
Ormecı A., Cavus B., Akas R., İstemihan Z., İmanov Z., Senkal V., Nuriyev K., Bayraktar A., Kuelle C. B. , Keskin M., et al.
European review for medical and pharmacological sciences, vol.26, no.17, pp.6300-6309, 2022 (SCI-Expanded)
- II. **Cyclosporine Therapy as a Rescue Treatment in Steroid Refractory Acute Severe Ulcerative Colitis: A Real Life Data From a Tertiary Center**
Evirgen S., İliaz R., Akyuz F., Cavus B., Gokturk S., Ormecı A., Soyer O. M. , Baran B., Pınarbasi B., Karaca C., et al.
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.33, no.6, pp.463-469, 2022 (SCI-Expanded)
- III. **A mysterious cause of recurrent acute liver dysfunction for over a decade**
Dirim A. B. , Kalaycı T., Guzel Dirim M., Demir S., Cavus B., Cifcibasi Ormecı A., Akyuz F., Kaymakoglu S.
GASTROENTEROLOGY REPORT, vol.10, 2022 (SCI-Expanded)
- IV. **Is anterior segment OCT superior to slit-lamp biomicroscopic examination for Kayser Flesicher ring in Wilson's disease?**
Ormecı A., Bayraktar S., Isik A. O. , Cavus B., Akas R., İstemihan Z., Sarıdal M. K. , Akyuz F., Besisik F., Kaymakoglu S., et al.
European Review for Medical and Pharmacological Sciences, vol.26, no.14, pp.5178-5185, 2022 (SCI-Expanded)
- V. **Can Interferon Therapy Change the Natural Course of Hepatitis Delta Infection?: a Clinical and Pathological Study**
BAKKALOĞLU O. K. , Yildirim O., Cavus B., Evirgen S., Gokturk S., Ormecı A., Soyer O., Akyuz F., Demir K., Kaymakoglu

S., et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol.66, no.1, 2022 (SCI-Expanded)

- VI. **The Relationship between Ocular Vascular Changes and the Levels of Malondialdehyde and Vascular Endothelial Growth Factor in Patients with Inflammatory Bowel Disease**
Sengul S., Poturoglu S., Samanci C., Ustabasioglu F., Koldas M., Duman A., Ormeci A.
OCULAR IMMUNOLOGY AND INFLAMMATION, vol.29, no.7-8, pp.1459-1463, 2021 (SCI-Expanded)
- VII. **Etiology of Cirrhosis in Turkey: A National Cohort Study**
YILDIRIM A. E. , ÜÇBİLEK E., Oruncu M. B. , TURAN İ., DEMİR M., Koksall A., UYANIKOĞLU A., Yilmaz N., AKARSU M., Tozlu M., et al.
JOURNAL OF HEPATOLOGY, vol.75, 2021 (SCI-Expanded)
- VIII. **The development of extraintestinal manifestation and related risk factors in Crohn's patients**
Kayar Y., Dertli R., Konur S., Agin M., Baran B., Ormeci A., Akyuz F., Demir K., Besisik F., Kaymakoglu S.
IRISH JOURNAL OF MEDICAL SCIENCE, vol.190, no.2, pp.597-604, 2021 (SCI-Expanded)
- IX. **What are the predictors for recurrence of Crohn's disease after surgery?**
Ozgur İ., Kulle C. B. , Buyuk M., Ormeci A., Akyuz F., Balik E., Bulut T., Keskin M.
MEDICINE, vol.100, no.14, 2021 (SCI-Expanded)
- X. **Prolonged Severe Watery Diarrhea in a Long-Term Myeloma Survivor: An Unforeseen Infection with Cystoisospora belli**
Tiryaki T. O. , Anil K. U. , Büyük M., Yıldırım A. Y. , Atasoy A., Çiftçi başı Örmeci A., Kalayoğlu Beşişik S.
TURKISH JOURNAL OF HEMATOLOGY, vol.38, no.2, pp.171-173, 2021 (SCI-Expanded)
- XI. **Myeloma and Cystoisospora belli REPLY**
Tiryaki T. O. , Anil K. U. , Buyuk M., Yildirim A. Y. , Atasoy A., Ormeci A., Besisik S. K.
TURKISH JOURNAL OF HEMATOLOGY, vol.38, no.3, pp.230, 2021 (SCI-Expanded)
- XII. **Efficacy of adalimumab in mild-to-moderate inflammatory bowel disease: Real-life data from single-centre experience in the long-term period**
Akyuz F., Ormeci A., Namazova N., Guzel M., Abbasgoulizadeh A., Tahincioglu L., Alaskarli S., Gurel E., Bilgin E., Atasoy A., et al.
JOURNAL OF CROHNS & COLITIS, vol.14, 2020 (SCI-Expanded)
- XIII. **The effect of liver test abnormalities on the prognosis of COVID-19.**
Medetalibeyoglu A., Catma Y., Senkal N., Ormeci A., Cavus B., Kose M., Bayramlar O. F. , Yildiz G., Akyuz F., Kaymakoglu S., et al.
Annals of hepatology, vol.19, no.6, pp.614-621, 2020 (SCI-Expanded)
- XIV. **Gastroesophageal Reflux in Asymptomatic Patients with Diabetes: An Impedance Study Diabetes, Obesity and Gastroesophageal Reflux**
Gokturk S., Akyuz F., Arici S., Alpaslan B., Ormeci A., Soyer O. M. , Evirgen S., Cavus B., Uzun A. K. , Gul N., et al.
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, vol.128, no.1, pp.52-58, 2020 (SCI-Expanded)
- XV. **Risk factors associated with progression to intestinal complications of Crohn disease**
Kayar Y., Baran B., Ormeci A., Akyuz F., Demir K., Besisik F., Kaymakoglu S.
CHINESE MEDICAL JOURNAL, vol.132, no.20, pp.2423-2429, 2019 (SCI-Expanded)
- XVI. **Usage of HCV viremic organs in liver transplantation to anti-HCV negative recipients: The current status and review of literature**
ÇİFCİBAŞI ÖRMECİ A., Yildiz C., Seber B., Gurakar M., Simsek C., Gurakar A.
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.30, no.9, pp.771-775, 2019 (SCI-Expanded)
- XVII. **Inflammatory bowel disease and mycobacteria: how much can we trust isoniazid prophylaxis during antitumor necrosis factor therapy?**
Akyuz F., Cavus B., İliaz R., Soyer O. M. , Ormeci A., Evirgen S., Onder S., Koksallan K., Keskin M., Karaca C., et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, vol.31, no.7, pp.777-780, 2019 (SCI-Expanded)
- XVIII. **Does the number of mucosal immune cells differ in irritable bowel syndrome and its subtypes?**
İLİAZ R., AKYÜZ F., Yeğen G., ÖRMECİ A., GÖKTÜRK S., AKYÜZ Ü., BARAN B., MUTLUAY Ö., EVİRGEN S., KARACA Ç., et al.
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.29, no.4, pp.384-391, 2018 (SCI-Expanded)

- XIX. **Role of biochemistry and cytological analysis of cyst fluid for the differential diagnosis of pancreatic cysts A retrospective cohort study**
Soyer O. M. , Baran B., Ormeci A., Sahin D., Gokturk S., Evirgen S., Basar R., Firat P., Akyuz F., Demir K., et al.
MEDICINE, vol.96, no.1, 2017 (SCI-Expanded)
- XX. **A rare congenital liver anomaly: Hypoplasia of left hepatic lobe**
Ormeci T., Erdogan S. T. , ÇİFCİBAŞI ÖRMECİ A., Aygun C.
JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION, vol.66, no.12, pp.1662-1664, 2016 (SCI-Expanded)
- XXI. **Predictors of treatment requirement in HBeAg-negative chronic hepatitis B patients with persistently normal alanine aminotransferase and high serum HBV DNA levels**
Ormeci A., Aydın Y., Sumnu A., Baran B., Soyer O. M. , Pinarbasi B., Gokturk S., Gulluoglu M., Onel D., Badur S., et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, vol.52, pp.68-73, 2016 (SCI-Expanded)
- XXII. **Retention during capsule endoscopy: Is it a real problem in routine practice?**
Ormeci A., Akyuz F., Baran B., Gokturk S., Ormeci T., Pinarbasi B., Soyer O. M. , Evirgen S., Akyuz U., Karaca C., et al.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, vol.44, no.4, pp.968-975, 2016 (SCI-Expanded)
- XXIII. **Can Helicobacter pylori be eradicated with high-dose proton pump inhibitor in extensive metabolizers with the CYP2C19 genotypic polymorphism?**
ORMECİ A., Emrence Z., BARAN B., SOYER O., GOKTURK S., EVIRGEN S., AKYUZ F., KARACA C., BESISIK F., KAYMAKOGLU S., et al.
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, vol.20, no.9, pp.1795-1797, 2016 (SCI-Expanded)
- XXIV. **Comparison of the efficacy of 12 months and longer courses of interferon therapy for the treatment of chronic delta hepatitis: a retrospective cohort study**
Soyer O. M. , Baran B., Ormeci A., Gokturk S., Aydın E., Onel D., Gulluoglu M., Karaca C., Akyuz F., Demir K., et al.
POSTGRADUATE MEDICINE, vol.128, no.4, pp.432-438, 2016 (SCI-Expanded)
- XXV. **Effect of cytochrome P450 2C19 polymorphisms on the Helicobacter pylori eradication rate following two-week triple therapy with pantoprazole or rabeprazole**
Ormeci A., Emrence Z., Baran B., Gokturk S., Soyer O. M. , Evirgen S., Akyuz F., Karaca C., Besisik F., Kaymakoglu S., et al.
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, vol.20, no.5, pp.879-885, 2016 (SCI-Expanded)
- XXVI. **Steroid-refractory inflammatory bowel disease is a risk factor for CMV infection**
Ormeci A., Akyuz F., BARAN B., SOYER O., GÖKTÜRK S., ONEL M., ONEL D., AGACFIDAN A., DEMIRCI M., Yegen G., et al.
European Review for Medical and Pharmacological Sciences, vol.20, no.5, pp.858-865, 2016 (SCI-Expanded)
- XXVII. **Tenofovir disoproxil fumarate has a substantial efficacy against multidrug-resistant strains of hepatitis B virus**
Baran B., Soyer O. M. , Ormeci A., Gokturk S., Evirgen S., Akyuz F., Karaca C., Demir K., Besisik F., Onel D., et al.
LIVER INTERNATIONAL, vol.35, no.10, pp.2265-2274, 2015 (SCI-Expanded)
- XXVIII. **Small bowel mucosal damage in familial Mediterranean fever: results of capsule endoscopy screening**
Demir A., Akyuz F., Gokturk S., Evirgen S., Akyuz U., Ormeci A., Soyer O., Karaca C., Demir K., Gundogdu G., et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, vol.49, no.12, pp.1414-1418, 2014 (SCI-Expanded)
- XXIX. **Effects of Polymorphisms in Interferon lambda 3 (Interleukin 28B) on Sustained Virologic Response to Therapy in Patients With Chronic Hepatitis D Virus Infection**
Yilmaz E., Baran B., Soyer O. M. , Onel M., Onel D., Ormeci A., Gokturk S., Evirgen S., Akyuz F., Demir K., et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, vol.12, no.10, pp.1753-1758, 2014 (SCI-Expanded)
- XXX. **Clinical significance of serum hepatocyte growth factor (HGF) levels in hepatocellular carcinoma**
Karabulut S., Tas F., Akyuz F., Ormeci A., Serilmez M., Soydinc H. O. , Vatanserver S., Yasasever V.
TUMOR BIOLOGY, vol.35, no.3, pp.2327-2333, 2014 (SCI-Expanded)
- XXXI. **Treatment failure may lead to accelerated fibrosis progression in patients with chronic hepatitis C**
Baran B., Gulluoglu M., Soyer O. M. , Ormeci A., Gokturk S., Evirgen S., Yesil S., Akyuz F., Karaca C., Demir K., et al.

JOURNAL OF VIRAL HEPATITIS, vol.21, no.2, pp.111-120, 2014 (SCI-Expanded)

- XXXII. **Efficacy of tenofovir in adefovir-experienced patients compared with treatment-naive patients with chronic hepatitis B**
KESKİN O., Ormeci A., Baran B., Kabacam G., Tuzun A., Karatayli E., Akyuz F., Karatayli S., BOZDAYI A. M. , Onel D., et al.
ANTIVIRAL THERAPY, vol.19, no.6, pp.543-550, 2014 (SCI-Expanded)
- XXXIII. **Effect of Genotypic Differences in CYP2C19 and on Cure Rates for Helicobacter pylori Infection by Triple Therapy With Different Proton Pump Inhibitors**
Demir K., ORMECI A., Emrence Z., Gokturk S., Baran B., SOYER O. M. , Akyuz F., Karaca C., BESISIK F., Kaymakoglu S., et al.
GASTROENTEROLOGY, vol.144, no.5, 2013 (SCI-Expanded)
- XXXIV. **Efficacy of Tenofovir in Patients with Lamivudine Failure Is Not Different from That in Nucleoside/Nucleotide Analogue-Naive Patients with Chronic Hepatitis B**
Baran B., Soyer O. M. , Ormeci A., Gokturk S., Evirgen S., Bozbey H. U. , Akyuz F., Karaca C., Demir K., Besisik F., et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol.57, no.4, pp.1790-1796, 2013 (SCI-Expanded)
- XXXV. **Efficacy of pegylated interferon-alpha treatment for 24 months in chronic delta hepatitis and predictors of response**
Karaca C., Soyer O. M. , Baran B., Ormeci A., Gokturk S., Aydin E., Evirgen S., Akyuz F., Demir K., Besisik F., et al.
ANTIVIRAL THERAPY, vol.18, no.4, pp.561-566, 2013 (SCI-Expanded)
- XXXVI. **Treatment of aortic valve stenosis and gastrointestinal bleeding by transcatheter aortic valve implantation in Heyde syndrome**
Gul M., Surgit O., Ozal E., Ormeci A., Bakir I.
ANADOLU KARDIOLOJİ DERGİSİ-THE ANATOLIAN JOURNAL OF CARDIOLOGY, vol.12, no.8, pp.691-693, 2012 (SCI-Expanded)

Articles Published in Other Journals

- I. **EVALUATION OF HELICOBACTER PYLORI FREQUENCY AND GASTRIC ANTRUM PATHOLOGY FINDINGS IN PATIENTS WITH PORTAL HYPERTENSION**
Cavus B., Ormeci A., Evirgen S., Iliaz R., Atasoy A., Yegen G., Demir K., Besisik S. F. , Kaymakoglu S., Akyuz F.
JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESİ DERGİSİ, vol.85, no.2, pp.211-215, 2022 (ESCI)
- II. **ANALYSIS OF GENOTYPE, SUBGENOTYPE AND SEROTYPE OF OCCULT HEPATITIS B VIRUS**
Cakal B., Atasoy A., Cavus B., Ormeci A., Poda M., Bulakci M., Gulluoglu M., Gunver M. G. , Akyuz F.
JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESİ DERGİSİ, vol.84, no.3, pp.402-410, 2021 (ESCI)
- III. **IMPLICATION OF SERUM IL-17 LEVELS IN CHRONIC HEPATITIS B PATIENTS**
ÇAKAL B., ÇAVUŞ B., Atasoy A., Ormeci A., BULAKÇI M., GÜLLÜOĞLU M., GÜNVER M. G. , AKYÜZ F.
JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESİ DERGİSİ, vol.84, no.1, pp.68-75, 2021 (ESCI)
- IV. **Current state and clinical outcome in Turkish patients with hepatocellular carcinoma**
Ekinci O., Baran B., Ormeci A., Soyer O. M. , Gokturk S., Evirgen S., Poyanli A., Gulluoglu M., Akyuz F., Karaca C., et al.
WORLD JOURNAL OF HEPATOLOGY, vol.10, no.1, pp.51-61, 2018 (ESCI)
- V. **What is the impact of capsule endoscopy in the long term period?**
Ormeci A., Akyuz F., Baran B., Gokturk S., Ormeci T., Pinarbasi B., Soyer O. M. , Evirgen S., Akyuz U., Karaca C., et al.
WORLD JOURNAL OF GASTROINTESTINAL ENDOSCOPY, vol.8, no.7, pp.344-348, 2016 (ESCI)
- VI. **A rare complication of interferon treatment: optic neuropathy**
Gokturk S., Atay K., ÇİFCİBAŞI ÖRMECİ A., Baran B., Soyer O. M. , AKYÜZ F., Karaca C., KAYMAKOĞLU S.
ANNALS OF GASTROENTEROLOGY, vol.24, no.4, pp.335, 2011 (ESCI)

Refereed Congress / Symposium Publications in Proceedings

- I. Bektaş E., Yılmaz A., Bilgin E., Mutlu Ü., Çavuş B., Çifcibaşı Örmeci A., Akyüz F., Kaymakoğlu S.
24. Ulusal İç Hastalıkları Kongresi, Antalya, Turkey, 19 - 23 October 2022, pp.136-137
- II. **HEMOFAGOSİTİK LENFOHİSTİYOSİTOZUN NADİR BİR SEBEBİ: VİSSERAL LEİSHMANİASİS**
Yılmaz A., Bektaş E., Bilgin E., Şenkal İ. V. , Çavuş B., Çifcibaşı Örmeci A., Beşişik S. F.
24. Ulusal İç Hastalıkları Kongresi, Antalya, Turkey, 19 - 23 October 2022, pp.118-119
- III. **REAL-WORLD DATA OF TENOFOVİR ALAFENAMIDE IN TREATMENT-NAIVE AND EXPERIENCED PATIENTS WITH CHRONIC HEPATİTİS B: MORE EFFICACY, LESS SIDE EFFECTS**
Bektaş E., Yılmaz A., Kıkılı C. İ. , Nuriyev K., İstemihan Z., Şenkal İ. V. , Çavuş B., Çifcibaşı Örmeci A., Akyüz F., Demir K., et al.
AASLD Liver Meeting , District Of Columbia, United States Of America, 4 - 08 November 2022, vol.76, pp.299
- IV. **Ön Segment Optik Koherans Tomografi (OCT), Wilson hastalığı tanısında Kayser Fleischer Halkası varlığını değerlendirmek için - Ehil oftalmolog gerekliliğine son verecek mi?**
Çifcibaşı Örmeci A., Bayraktar Ş., Işık A. O. , İstemihan Z., Sarıdal M. K. , Akas R., Çavuş B., Akyüz F., Beşişik S. F. , Kaymakoğlu S., et al.
38. Ulusal Gastroenteroloji Haftası, 9. Gastroenteroloji Cerrahisi Kongresi, Antalya, Turkey, 16 - 21 November 2021, pp.218
- V. **Budd-Chiari Sendromu'nda Hepatoselüler Kansere ve Mortalitenin Değerlendirilmesi**
İstemihan Z., Nuriyev K., Şenkal İ. V. , İmanov Z., Sarıdal M. K. , Akas R., Çavuş B., Çifcibaşı Örmeci A., Akyüz F., Demir K., et al.
38. Ulusal Gastroenteroloji Haftası, 9. Gastroenteroloji Cerrahisi Kongresi, Antalya, Turkey, 16 - 21 November 2021, pp.219
- VI. **Girişimsel Gastroenterolojik İşlemlerde Hastaların Doktor Tercihinde Cinsiyet Önemli mi?**
Kara İnci A., Zaralı S., Akyüz M., İmanov Z., Şenkal İ. V. , İstemihan Z., Nuriyev K., Çavuş B., Çifcibaşı Örmeci A., Akyüz F.
38. Ulusal Gastroenteroloji Haftası, 9. Gastroenteroloji Cerrahisi Kongresi, Antalya, Turkey, 16 - 21 November 2021, pp.204
- VII. **COMPARISON OF PROGNOSTIC SCORING SYSTEMS FOR PREDICTION OF SURVIVAL IN HEPATOCELLULAR CARCINOMA**
Baran B., Ekinci O., Soyer O. M. , Örmeci A., Gokturk S., Evirgen S., Poyanlı A., Gulluoglu M., Akyuz F., Karaca C., et al.
EASL International Liver Congress, Barcelona, Spain, 13 - 17 April 2016, vol.64
- VIII. **Chronic Renal Failure after Liver Transplantation in Long Term: Prevalence and Risk Factors.**
Gokturk S., Baran B., Örmeci A., Soyer O., Evirgen S., Ozden I., Akyuz F., Karaca C., Demir K., Kaymakoglu S., et al.
Joint International Congress of ILTS, ELITA and LICAGE, London, Canada, 4 - 07 June 2014, vol.20
- IX. **Evaluation of Small Bowel Mucosal Damage by Capsule Endoscopy in Familial Mediterranean Fever Patients**
Demir A., Besisik F., Gokturk S., Evirgen S., Akyuz U., Örmeci A., Soyer O. M. , Karaca C., Demir K., Gulluoglu M., et al.
55th Annual Meeting of the Society-for-Surgery-of-the-Alimentary-Tract (SSAT) / Digestive Disease Week (DDW), Illinois, United States Of America, 3 - 06 May 2014, vol.146
- X. **Is Diabetes Mellitus a Risk Factor for Gastroesophageal Reflux?**
Gokturk S., Besisik F., Arici S., Alpaslan B., Örmeci A., Soyer O. M. , Evirgen S., Cavus B., Uzum A. K. , Gul N., et al.
55th Annual Meeting of the Society-for-Surgery-of-the-Alimentary-Tract (SSAT) / Digestive Disease Week (DDW), Illinois, United States Of America, 3 - 06 May 2014, vol.146
- XI. **ENTECAVİR AND TENOFOVİR HAVE A COMPARABLE EFFICACY IN TREATMENT OF NUCLEOS(T)İDE ANALOGUE NAİVE PATİENTİS WITH CHRONIC HEPATİTİS B: A REAL LIFE EXPERIENCE**
Baran B., Soyer O. M. , Örmeci A., Gokturk S., Evirgen S., Akyuz F., Karaca C., Demir K., Gulluoglu M., Onel D., et al.
49th Annual International Liver Congress of the European-Association-for-the-Study-of-the-Liver, London, Canada, 9 - 13 April 2014, vol.60
- XII. **Baseline alfa-fetoprotein level is a strong predictor of vascular invasion and survival in patients with hepatocellular carcinoma**

Ekinci O., Baran B., Ormeci A., Soyer O. M., Gokturk S., Poyanli A., Gulluoglu M., Karaca C., Akyuz F., Demir K., et al.
64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases,
Washington, Kiribati, 1 - 05 November 2013, vol.58

- XIII. **The antiviral efficacy of entecavir is not influenced by prior treatment with nucleos(t)ide analogues in patients with chronic hepatitis B**
Baran B., Soyer O. M., Ormeci A., Gokturk S., Evirgen S., Akyuz F., Karaca C., Demir K., Besisik F., Onel D., et al.
64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases,
Washington, Kiribati, 1 - 05 November 2013, vol.58
- XIV. **Safety of Tenofovir in Renal Transplanted and Hemodialysis Patients with Chronic Hepatitis B**
Akyuz F., Gokturk S., Baran B., Ormeci A., Soyer O. M., Evirgen S., Karaca C., Demir K., Besisik F., Kaymakoglu S.
64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases,
Washington, Kiribati, 1 - 05 November 2013, vol.58
- XV. **Risk factors for significant liver fibrosis in genotype D HBeAg-negative chronic hepatitis B infection with persistently normal ALT and high serum HBVDNA levels**
Ormeci A., Akyuz F., Baran B., Soyer O. M., Gokturk S., Karaca C., Gulluoglu M., Onel D., Badur S., Demir K., et al.
64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases,
Washington, Kiribati, 1 - 05 November 2013, vol.58
- XVI. **Tenofovir disoproxil fumarate has a substantial efficacy against adefovir and multi-drug resistant strains of hepatitis B virus**
Baran B., Soyer O. M., Ormeci A., Gokturk S., Evirgen S., Akyuz F., Karaca C., Demir K., Besisik F., Onel D., et al.
64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases,
Washington, Kiribati, 1 - 05 November 2013, vol.58
- XVII. **Virological Suppression Does not Prevent the Development of Hepatocellular Carcinoma in Cirrhotic Patients with Genotype D Hepatitis B Infection**
Gokturk S., Basar R., Ucar A. R., Basgoze B. H., Altinkaynak M., Buyukballi P., Alpaslan B., Baran B., Ormeci A., Soyer O. M., et al.
64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases,
Washington, Kiribati, 1 - 05 November 2013, vol.58
- XVIII. **IL28B Polymorphisms and Influence on Sustained Virological Response to Interferon Therapy in Chronic DELTA Hepatitis**
Karaca C., Yilmaz E., Soyer O. M., Onel D., ÖNEL M., Baran B., ÇİFCİBAŞI ÖRMECİ A., Gokturk S., Evirgen S., AKYÜZ F., et al.
Digestive Disease Week / 28th Annual Residents and Fellows Research Conference of the Society-for-Surgery-of-the-Alimentary-Tract (SSAT), Florida, United States Of America, 18 - 21 May 2013, vol.144
- XIX. **Does Chemoprophylaxis Prevent Tuberculosis Reactivation in the Long Term Period of Anti-TNF Treatment?**
AKYÜZ F., Soyer O. M., Gokturk S., ÇİFCİBAŞI ÖRMECİ A., Evirgen S., Onder S. Y., Karaca C., DEMİR K., BEŞİŞİK S. F., KAYMAKOĞLU S.
Digestive Disease Week / 28th Annual Residents and Fellows Research Conference of the Society-for-Surgery-of-the-Alimentary-Tract (SSAT), Florida, United States Of America, 18 - 21 May 2013, vol.144
- XX. **TREATMENT FAILURE MAY LEAD TO ACCELERATED FIBROSIS PROGRESSION IN PATIENTS WITH CHRONIC HEPATITIS C**
Baran B., Gulluoglu M., Soyer O., Ormeci A., Gokturk S., Evirgen S., Yesil S., Akyuz F., Karaca C., Demir K., et al.
International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Amsterdam, Netherlands, 24 - 28 April 2013, vol.58
- XXI. **Number connection test-A and inhibitor control test are not efficient for diagnosis of minimal hepatic encephalopathy in cirrhotic patients**
Baran B., Ozcan E., Oztop N., Cakmak R., Soyer O. M., Ormeci A., Gokturk S., Karaca C., Akyuz F., Demir K., et al.
63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, United States Of America, 9 - 13 November 2012, vol.56
- XXII. **Response to tenofovir treatment of treatment-naive and adefovir experienced patients with chronic**

hepatitis b

KESKİN O., Ormeci A., Kabacam G., Akyuz F., Aniktar H., Karaca C., İDİLMAN R., Kaymakoglu S., Yurdaydin C.
63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, United States Of America, 9 - 13 November 2012, vol.56

XXIII. Success of Two Different Endoscopic Submucosal Resection Methods in Gastric Subepithelial Lesions

Karaca C., Soyer O. M. , Akyuz F., Baran B., Ormeci A., Gokturk S., Demir K., Ozdil S., Besisik F., Kaymakoglu S.
Digestive Disease Week (DDW), California, United States Of America, 19 - 22 May 2012, vol.75, pp.136

XXIV. RESPONSE TO TENOFOVIR TREATMENT OF TREATMENT-NAIVE VS ADEFOVIR-RESISTANT VS SUBOPTIMAL RESPONDER PATIENTS WITH CHRONIC HEPATITIS B

Keskin O., Ormeci A., Kabacam G., Akyuz F., Aniktar H., Karaca C., Idilman R., Kaymakoglu S., Yurdaydin C.
47th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Barcelona, Spain, 18 - 22 April 2012, vol.56

Activities in Scientific Journals

Journal of Enterocolitis, Assistant Editor, 2021 - Continues

Hepatology Forum, Assistant Editor, 2019 - Continues

Metrics

Publication: 66

Citation (WoS): 289

Citation (Scopus): 274

H-Index (WoS): 10

H-Index (Scopus): 11